InvestSMART

Cyclopharm Limited (ASX: CYC) - Announcements

- Current share price for CYC : $0.375

ASX company news and announcements for Cyclopharm Limited (CYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cyclopharm Limited (CYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cyclopharm Limited (CYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cyclopharm Limited (CYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$47 Annual Report to shareholders 26 Mar 2024 2:09PM $1.780 $0.375 fallen by 78.93%
$47 Voluntary Escrow Shares to be Released 25 Mar 2024 12:02PM $1.790 $0.375 fallen by 79.05%
$47 Date of Annual General Meeting 25 Mar 2024 11:07AM $1.780 $0.375 fallen by 78.93%
$47 First USA Patients Imaged with Technegas 19 Mar 2024 9:59AM $1.800 $0.375 fallen by 79.17%
$47 S&P DJI Announces March 2024 Quarterly Rebalance 1 Mar 2024 5:03PM $1.800 $0.375 fallen by 79.17%
$47 CYC Results Summary 28 Feb 2024 8:10AM $1.800 $0.375 fallen by 79.17%
$47 Preliminary Final Report 28 Feb 2024 8:09AM $1.800 $0.375 fallen by 79.17%
$47 Initial Director's Interest Notice 19 Feb 2024 3:24PM $1.850 $0.375 fallen by 79.73%
$47 CYC Board Changes 19 Feb 2024 3:24PM $1.850 $0.375 fallen by 79.73%
$47 Cyclopharm Appoints Jason Smith as CFO 12 Feb 2024 1:12PM $1.800 $0.375 fallen by 79.17%
$47 Cyclopharm to Present at Euroz Hartleys Healthcare Forum 6 Feb 2024 9:26AM $1.715 $0.375 fallen by 78.13%
$47 Cyclopharm Trading and USA Launch Update 5 Feb 2024 4:50PM $1.715 $0.375 fallen by 78.13%
$47 CYC and Yale Translational Research Partner on Technegas 29 Jan 2024 9:14AM $1.850 $0.375 fallen by 79.73%
$47 Cyclopharm Signs First USA Contract for Technegas 5 Dec 2023 8:43AM $2.000 $0.375 fallen by 81.25%
$47 Change of Director's Interest Notice 1 Dec 2023 11:47AM $2.020 $0.375 fallen by 81.44%
$47 Application for quotation of securities - CYC 1 Dec 2023 11:45AM $2.020 $0.375 fallen by 81.44%
$47 Technegas USA Commercialisation Update 15 Nov 2023 10:23AM $2.150 $0.375 fallen by 82.56%
$47 Change of Director's Interest Notice 2 Nov 2023 8:57AM $2.080 $0.375 fallen by 81.97%
$47 Change of Director's Interest Notice 1 Nov 2023 6:00PM $2.080 $0.375 fallen by 81.97%
$47 CYC USFDA Approval Webinar Presentation 5 Oct 2023 12:36PM $2.550 $0.375 fallen by 85.29%
$47 FDA Technegas Approval Webinar 3 Oct 2023 10:57AM $2.980 $0.375 fallen by 87.42%
$47 SNMMI Announcement Regarding USFDA Approval of Technegas 3 Oct 2023 8:40AM $2.870 $0.375 fallen by 86.93%
$47 Cyclopharm Receives USFDA Approval for Technegas 2 Oct 2023 8:26AM $2.830 $0.375 fallen by 86.75%
$47 Investor Presentation Correction 26 Sep 2023 10:06AM $2.880 $0.375 fallen by 86.98%
$47 Investor Presentation Correction 26 Sep 2023 10:06AM $2.880 $0.375 fallen by 86.98%

151 - 175 of 614 results

Page 7 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.